Marko Laakso
Overview
Explore the profile of Marko Laakso including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
580
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cervera A, Rantanen V, Ovaska K, Laakso M, Nunez-Fontarnau J, Alkodsi A, et al.
Bioinformatics
. 2019 Feb;
35(19):3815-3817.
PMID: 30793160
Summary: Anduril is an analysis and integration framework that facilitates the design, use, parallelization and reproducibility of bioinformatics workflows. Anduril has been upgraded to use Scala for pipeline construction, which...
2.
Singh A, Mandoli A, Prange K, Laakso M, Martens J
Oncotarget
. 2016 Dec;
8(8):12855-12865.
PMID: 28030795
Chromosomal translocations are one of the hallmarks of acute myeloid leukemia (AML), often leading to gene fusions and expression of an oncofusion protein. Over recent years it has become clear...
3.
Fleischer T, Klajic J, Aure M, Louhimo R, Pladsen A, Ottestad L, et al.
Oncotarget
. 2016 Dec;
8(1):1074-1082.
PMID: 27911866
Breast cancer patients with Luminal A disease generally have a good prognosis, but among this patient group are patients with good prognosis that are currently overtreated with adjuvant chemotherapy, and...
4.
Louhimo R, Laakso M, Belitskin D, Klefstrom J, Lehtonen R, Hautaniemi S
BioData Min
. 2016 May;
9:21.
PMID: 27231484
Background: Genomic alterations affecting drug target proteins occur in several tumor types and are prime candidates for patient-specific tailored treatments. Increasingly, patients likely to benefit from targeted cancer therapy are...
5.
Liu C, Louhimo R, Laakso M, Lehtonen R, Hautaniemi S
BMC Cancer
. 2015 May;
15:319.
PMID: 25928379
Background: Histologically similar tumors even from the same anatomical position may still show high variability at molecular level hindering analysis of genome-wide data. Leveling the analysis to a gene regulatory...
6.
Louhimo R, Laakso M, Heikkinen T, Laitinen S, Manninen P, Rogojin V, et al.
BMC Syst Biol
. 2013 Nov;
7 Suppl 1:S2.
PMID: 24267921
Background: Cancers are complex diseases arising from accumulated genetic mutations that disrupt intracellular signaling networks. While several predisposing genetic mutations have been found, these individual mutations account only for a...
7.
Sahu B, Laakso M, Pihlajamaa P, Ovaska K, Sinielnikov I, Hautaniemi S, et al.
Cancer Res
. 2012 Dec;
73(5):1570-80.
PMID: 23269278
The forkhead protein FoxA1 has functions other than a pioneer factor, in that its depletion brings about a significant redistribution in the androgen receptor (AR) and glucocorticoid receptor (GR) cistromes....
8.
Jamshidi M, Schmidt M, Dork T, Garcia-Closas M, Heikkinen T, Cornelissen S, et al.
Int J Cancer
. 2012 Oct;
132(9):2044-55.
PMID: 23034890
Germline variation in the TP53 network genes PRKAG2, PPP2R2B, CCNG1, PIAS1 and YWHAQ was previously suggested to have an impact on drug response in vitro. Here, we investigated the effect...
9.
Karhemo P, Ravela S, Laakso M, Ritamo I, Tatti O, Makinen S, et al.
J Proteomics
. 2012 Jul;
77:87-100.
PMID: 22813880
Details of metastasis, the deadliest aspect of cancer, are unclear. Cell surface proteins play central roles in adhesive contacts between the tumor cell and the stroma during metastasis. We optimized...
10.
Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Rannikko A, et al.
EMBO J
. 2011 Sep;
30(19):3962-76.
PMID: 21915096
High androgen receptor (AR) level in primary tumour predicts increased prostate cancer-specific mortality. However, the mechanisms that regulate AR function in prostate cancer are poorly known. We report here a...